Targeted institutions MSI serves top-tier academic and research institutions as well as large pharma, providing an opening to expand into leading universities, national labs, and R&D arms of pharma companies that require in vivo monitoring and gait analysis for CNS, pain, and neurodegenerative research.

Clinical translation focus The company’s instruments accelerate preclinical translation, suggesting a sales angle around streamlined study timelines, improved animal welfare, and higher data quality to attract institutions aiming to speed up CNS and movement disorder pipelines.

High value use cases ECGenie and DigiGait address clear disease areas and model types, enabling targeted cross-sell opportunities across TBI, Parkinson’s, Huntington’s, epilepsy, ALS, and muscular dystrophy programs, as well as toxicity and drug evaluation studies.

Global and public sector A diverse customer base including NIH, universities worldwide, and government agencies indicates opportunity for expansion through grant-funded projects, multi-site collaborations, and favorable procurement channels.

Digital and commerce fit Existing tech stack and e-commerce presence (Shopify, WooCommerce, WordPress) enable scalable online demonstrations, trials, and purchasing for new customers, plus potential for bundled service offerings and maintenance plans.